U.S., May 22 -- ClinicalTrials.gov registry received information related to the study (NCT06982859) titled 'A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus' on May 14.
Brief Summary: The primary objective of Study GZQG is to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Diabetes Mellitus
Insulin Sensitivity
Intervention:
DRUG: Retatrutide
Administered SC
DRUG: Semaglutide
Administered SC
DRUG: Placebo
Administered SC
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Eli Lilly and Company
Published by HT...